Antonio M. Risitano

16.2k total citations · 2 hit papers
200 papers, 8.1k citations indexed

About

Antonio M. Risitano is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Antonio M. Risitano has authored 200 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Immunology, 133 papers in Hematology and 70 papers in Genetics. Recurrent topics in Antonio M. Risitano's work include Complement system in diseases (123 papers), Blood groups and transfusion (56 papers) and Hematopoietic Stem Cell Transplantation (47 papers). Antonio M. Risitano is often cited by papers focused on Complement system in diseases (123 papers), Blood groups and transfusion (56 papers) and Hematopoietic Stem Cell Transplantation (47 papers). Antonio M. Risitano collaborates with scholars based in Italy, United States and United Kingdom. Antonio M. Risitano's co-authors include Jaroslaw P. Maciejewski, Neal S. Young, Hubert Schrezenmeier, John D. Lambris, Peter Hillmen, Robert A. Brodsky, Jeff Szer, Jörg Schubert, Lucio Luzzatto and Régis Peffault de Latour and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Antonio M. Risitano

189 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2006 878 citations Peter Hillmen, Neal S. Young et al. profile →
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2021 249 citations Peter Hillmen, Jeff Szer et al. profile →

Peers

Countries citing papers authored by Antonio M. Risitano

Since Specialization

Citations

This map shows the geographic impact of Antonio M. Risitano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio M. Risitano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio M. Risitano more than expected).

Fields of papers citing papers by Antonio M. Risitano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio M. Risitano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio M. Risitano. The network helps show where Antonio M. Risitano may publish in the future.

Co-authorship network of co-authors of Antonio M. Risitano

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio M. Risitano. A scholar is included among the top collaborators of Antonio M. Risitano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio M. Risitano. Antonio M. Risitano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations 2025 ·Bone Marrow Transplantation ·Raffaella Greco, Annalisa Ruggeri, Donal P. McLornan, John A. Snowden, Tobias Alexander, Emanuele Angelucci, Diana Averbuch, Ali Bazarbachi, Mette D. Hazenberg, Krzysztof Kałwak, Michelle Kenyon, (unknown), Bénédicte Neven, Paolo Pedrazzoli, Zinaida Perić, Antonio M. Risitano, Isabel Sánchez‐Ortega, Fabio Ciceri, Anna Sureda	0
2	Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study 2024 ·Blood ·Nichola Cooper, David J. Kuter, Henrik Frederiksen, (unknown), (unknown), Wilma Barcellini, Joan Cid, Catherine M. Broome, (unknown), Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M. Risitano, Sangeeta Sawhney, Quentin A. Hill, Deepthi Jayawardene, (unknown), J. Zhao, Ahmed Daak	6
3	Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT 2024 ·Bone Marrow Transplantation ·Jakob Passweg, Helen Baldomero, Fabio Ciceri, Rafael de la Cámara, Bertram Glaß, Raffaella Greco, Mette D. Hazenberg, Krzysztof Kałwak, Donal P. McLornan, Bénédicte Neven, Zinaida Perić, Antonio M. Risitano, Annalisa Ruggeri, John A. Snowden, Anna Sureda	27
4	Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT 2024 ·Bone Marrow Transplantation ·Jakob Passweg, Helen Baldomero, Tobias Alexander, Emanuele Angelucci, Diana Averbuch, Ali Bazarbachi, Fabio Ciceri, Raffaella Greco, Mette D. Hazenberg, Krzysztof Kałwak, Donal P. McLornan, Antonio M. Risitano, Annalisa Ruggeri, John A. Snowden, Anna Sureda	1
5	Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition 2024 ·Blood ·Alexander Röth, Guangsheng He, Andrés Brodsky, Chatree Chai‐Adisaksopha, (unknown), Anna Gayà, Martin Höglund, Richard Kelly, (unknown), Je‐Hwan Lee, Naoshi Obara, Antonio M. Risitano, (unknown), (unknown), Brittany Gentile, Zilu Zhang, Bing Han, Sasha Sreckovic	0
6	Categorization of Hematological Responses to Oral Iptacopan Monotherapy in Anti-C5-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia in the Phase III APPLY-PNH Trial and Complement Inhibitor-Naïve Patients in the Phase III APPOINT-PNH Trial 2023 ·Blood ·Antonio M. Risitano, Bing Han, Austin Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Carlos de Castro, Jaroslaw P. Maciejewski, Josefin Snellman, Ranjan Tiwari, Marion Dahlke, Régis Peffault de Latour	4
7	PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL 2023 ·HemaSphere ·Antonio M. Risitano, David J. Araten, David J. Kuter, Bhumika J. Patel, Régis Peffault de Latour, Marion Dahlke, (unknown), (unknown), Samopriyo Maitra, Austin Kulasekararaj	1
8	Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial 2022 ·The Lancet Haematology ·Régis Peffault de Latour, Jeff Szer, Ilene C. Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean‐Jacques Kiladjian, Carlos M. de Castro, Hisakazu Nishimori, Temitayo Ajayi, Mohammed Al-Adhami, Pascal Deschatelets, Cedric Francois, F Grossi, Antonio M. Risitano, Peter Hillmen	43
9	Dyskeratosis congenita and squamous cell carcinoma of the mandibular alveolar ridge 2021 ·BMJ Case Reports ·(unknown), Antonio M. Risitano, Chiara Copelli	5
10	Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation 2021 ·Transplantation and Cellular Therapy ·(unknown), Mahmoud Aljurf, (unknown), Mansour Alfayez, Andrea Bacigalupo, Riad El Fakih, Hubert Schrezenmeier, Syed Osman Ahmed, Éliane Gluckman, (unknown), Britta Höchsmann, Constantijn J.M. Halkes, Josu de la Fuente, (unknown), Simone Cesaro, Jakob Passweg, Carlo Dufour, Antonio M. Risitano, John F. DiPersio, Ibraheem Motabi	12
11	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia 2020 ·Clinical Cancer Research ·Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Emanuele Angelucci, Boris V. Afanasyev, Jan J. Cornelissen, Simona Sica, Ellen Meijer, Fabio Ciceri, Gwendolyn Van Gorkom, Nicolaus Kröger, Hans Martin, Pietro Pioltelli, Antonio M. Risitano, Jonathan Canaani, Bipin N. Savani, Jaime Sanz, Mohamad Mohty	26
12	Hepatitis-Associated Aplastic Anemia 2020 ·Hematology/Oncology and Stem Cell Therapy ·(unknown), Carlo Dufour, Antonio M. Risitano, (unknown), Mahmoud Aljurf	17
13	Eltrombopag for post-transplant cytopenias due to poor graft function 2019 ·Bone Marrow Transplantation ·Serena Marotta, Luana Marano, (unknown), Fabiana Cacace, Camilla Frieri, (unknown), (unknown), (unknown), (unknown), Fabrizio Pane, Antonio M. Risitano	44
14	Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention 2015 ·European Journal of Clinical Investigation ·Dimitrios C. Mastellos, Despina Yancopoulou, Petros Kokkinos, Markus Huber‐Lang, George Hajishengallis, (unknown), Florea Lupu, Bo Nilsson, Antonio M. Risitano, Daniel Ricklin, John D. Lambris	170
15	Aplastic Anemia: Immunosuppressive Therapy in 2010 2011 ·SHILAP Revista de lepidopterología ·Antonio M. Risitano, Fabiana Perna	3
16	Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria 2007 ·Blood ·Robert A. Brodsky, Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gayà, Luke Coyle, Carlos de Castro Lozano, Chieh‐Lin Fu, Jaroslaw P. Maciejewski, Monica Bessler, (unknown), Russell P. Rother, Peter Hillmen	457
17	Function and Malfunction of Hematopoietic Stem Cells in Primary Bone Marrow Failure Syndromes 2007 ·Current Stem Cell Research & Therapy ·Antonio M. Risitano, Jaroslaw P. Maciejewski, Carmine Selleri, Bruno Rotoli	35
18	Molecular Analysis of TCR Clonotypes in LGL: A Clonal Model for Polyclonal Responses 2004 ·The Journal of Immunology ·Christine L. O’Keefe, Magdalena Plašilová, Marcin W. Włodarski, Antonio M. Risitano, Alexander Rodríguez, (unknown), Neal S. Young, Eric D. Hsi, Jaroslaw P. Maciejewski	54
19	Influence of loop size on the stability of intramolecular DNA quadruplexes 2004 ·Nucleic Acids Research ·Antonio M. Risitano	196
20	In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR β-CDR3 sequencing 2004 ·The Lancet ·Antonio M. Risitano, Jaroslaw P. Maciejewski, Spencer Green, Magdalena Plašilová, Weihua Zeng, Neal S. Young	199

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact